Keystone Heart is focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, atrial fibrillation ablation and other structural heart procedures.

Latest News

Share this

Press Release

TriGuard Cerebral Protection Device Shows Reduction in Stroke Rate and Improvement in Patients’ Neurological Outcomes in TAVR Procedures

Benefits of Keystone Heart’s TriGuard neuroprotection during TAVR in reducing stroke, CNS infarction and infarction size are supported by results from pooled analysis presented at EuroPCR 2016 TriGuard Cerebral Protection Device Shows Reduction in Stroke Rate and Improvement in Patients’ Neurological Outcomes in TAVR Procedures Benefits of...

Data Presented at ACC Demonstrates Benefits of Keystone Heart’s TriGuard™ Cerebral Protection Device during TAVR

Keystone Heart today announced that its CE marked TriGuard™ Cerebral Protection Device has improved in-hospital safety outcomes and cognitive scores at discharge during Transcatheter Aortic Valve Replacement (TAVR). Based on changes in NIH Stroke Scale, patients protected with TriGuard had 10% absolute reduction in stroke (4.9%...

Keystone Heart’s TriGuard™ Cerebral Protection Device Receives CE Marking

  CE Marking for the TriGuard™ device, devised to minimize the risk of brain damage during TAVR, enables commencement of commercial use Recent data demonstrates considerable reduction of new brain lesion volume during protected TAVR procedures performed with the TriGuard medical device Keystone Heart’s TriGuard™ Cerebral Protection Device...

New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR

New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR. New clinical data presented from the DEFLECT-I study demonstrates that Keystone Heart’s TriGuard™ Cerebral Protection Device reduces brain lesion volume during TAVR (Transcatheter Aortic Valve Replacement) procedures when compared to historical...